I want to thank Drs. Marino et al. for their interest and kind words. As they emphasize, the oncological aspect of reduction mammaplasty (RM) is an important consideration. In breast hypertrophy, by reducing the amount of normal breast tissue or breast tissue with increased risk of developing breast cancer, the subsequent risk for breast cancer is diminished, although other unknown factors contribute.
1Combined preoperative screening and histological examination of the specimen is supported to detect occult breast carcinoma in RM patient populations.
- Muir T.M.
- Tresham J.
- Fritschi L.
- Wylie E.
Screening for breast cancer post reduction mammoplasty.
Clin Radiol. 2010; 65: 198-205
2However, if a selective approach is used based on age or family history, it is somewhat unclear which patients without previous history of precancerous or cancerous findings should be included. Nevertheless, the value of negative preoperative screening mammography or other factors has been questioned by Dini et al., as all patients in their study with abnormal histological findings were negative for preoperative screening, history of breast carcinoma or intraoperative findings.
- Hennedige A.A.
- Kong T.Y.
- Gandhi A.
Oncological screening for bilateral breast reduction: a survey of practice variations in UK breast and plastics surgeons 2009.
J Plast Reconstr Aesthet Surg. 2011; 64: 878-883
3When pathological examination is performed, it should accurately focus on enabling further oncoplastic procedures and oncological treatments.
- Dini M.
- Agostini T.
- Marino G.
- Quercioli F.
Unsuspected breast carcinoma in reduction mammaplasty specimens and the role of pathologic examination.
Plast Reconstr Surg. 2011; 128 (815-6; author reply): 17-18
4Nonetheless, the cost of finding an occult breast cancer by routine and laborious pathological screening of RM specimens has been questioned.
- Slezak S.
- Bluebond-Langner R.
Occult carcinoma in 866 reduction mammaplasties: preserving the choice of lumpectomy.
Plast Reconstr Surg. 2011; 127: 525-530
- Koltz P.F.
- Girotto J.A.
The price of pathology: is screening all breast reduction specimens cost effective.
Plast Reconstr Surg. 2010; 125 (1575-6; author reply): 76-77
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Screening for breast cancer post reduction mammoplasty.Clin Radiol. 2010; 65: 198-205
- Oncological screening for bilateral breast reduction: a survey of practice variations in UK breast and plastics surgeons 2009.J Plast Reconstr Aesthet Surg. 2011; 64: 878-883
- Unsuspected breast carcinoma in reduction mammaplasty specimens and the role of pathologic examination.Plast Reconstr Surg. 2011; 128 (815-6; author reply): 17-18
- Occult carcinoma in 866 reduction mammaplasties: preserving the choice of lumpectomy.Plast Reconstr Surg. 2011; 127: 525-530
- The price of pathology: is screening all breast reduction specimens cost effective.Plast Reconstr Surg. 2010; 125 (1575-6; author reply): 76-77
Published online: March 30, 2012
© 2012 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- The cost utility of reduction mammaplastyJournal of Plastic, Reconstructive & Aesthetic SurgeryVol. 65Issue 9